Key result
Selective PDE4D negative allosteric modulators D159687 and D159797 demonstrated pro-cognitive effects in the object retrieval detour task in female Cynomolgus macaques.
Why the study?
Does selective PDE4D negative allosteric modulation improve cognitive performance in a non-human primate model?
Does selective PDE4D negative allosteric modulation improve cognitive performance in a non-human primate model?
Absolute Event Rate: 42% vs 22%
p-value: p=<0.05
Selective PDE4D negative allosteric modulators demonstrate pro-cognitive effects and favorable pharmacokinetics in non-human primates, supporting their development for brain disorders associated with cognitive decline.
May support PDE4 inhibition for cognitive circuits; leaves open translation from rodent models to clinical use.
Cyclic adenosine monophosphate (cAMP) signalling plays an important role in synaptic plasticity and information processing in the hippocampal and basal ganglia systems. The augmentation of cAMP signalling through the selective inhibition of phosphodiesterases represents a viable strategy to treat disorders associated with dysfunction of these circuits. The phosphodiesterase (PDE) type 4 inhibitor rolipram has shown significant pro-cognitive effects in neurological disease models, both in rodents and primates. However, competitive non-isoform selective PDE4 inhibitors have a low therapeutic index which has stalled their clinical development. Here, we demonstrate the pro-cognitive effects of selective negative allosteric modulators (NAMs) of PDE4D, D159687 and D159797 in female Cynomolgous macaques, in the object retrieval detour task. The efficacy displayed by these NAMs in a primate cognitive task which engages the corticostriatal circuitry, together with their suitable pharmacokinetic properties and safety profiles, suggests that clinical development of these allosteric modulators should be considered for the treatment of a variety of brain disorders associated with cognitive decline.
No takes yet. Share an insight, caveat, or question.
Sutcliffe et al. (2014) studied Cognitive performance (n=16). PDE4D Negative Allosteric Modulators (D159687 and D159797) vs. Vehicle was evaluated on Mean percent correct first reaches during difficult trials (Rolipram 0.03 mg/kg positive control data extracted) (p=<0.05). Selective PDE4D negative allosteric modulators D159687 and D159797 demonstrated pro-cognitive effects in the object retrieval detour task in female Cynomolgus macaques.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: